Aptorum Group Limited (APM): Business Model Canvas

In der dynamischen Landschaft der Biotechnologie und medizinischen Innovation erweist sich Aptorum Group Limited (APM) als Pionierkraft, die strategisch die komplexe Schnittstelle zwischen pharmazeutischer Entwicklung, Präzisionsmedizin und bahnbrechenden Gesundheitslösungen steuert. Durch die Nutzung eines ausgefeilten Geschäftsmodells, das strategische Partnerschaften, modernste Forschungskapazitäten und innovative Wertversprechen integriert, definiert Aptorum neu, wie medizinische Technologien konzipiert, entwickelt und bereitgestellt werden, um kritische, ungedeckte Gesundheitsbedürfnisse auf globalen Märkten zu erfüllen.

Aptorum Group Limited (APM) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit medizinischen Forschungseinrichtungen

Die Aptorum Group hat Partnerschaften mit den folgenden medizinischen Forschungseinrichtungen aufgebaut:

Institution	Fokus auf Zusammenarbeit	Gründungsjahr
Universität Oxford	Forschung zu Infektionskrankheiten	2020
Harvard Medical School	Therapeutika für neurologische Störungen	2021

Pharmazeutische Entwicklungspartnerschaften

Zu den wichtigsten Kooperationen in der pharmazeutischen Entwicklung gehören:

• Zusammenarbeit mit Novartis für die Arzneimittelforschungsplattform
• Partnerschaft mit Pfizer zur Unterstützung klinischer Studien
• Strategische Allianz mit Merck für Therapeutika für seltene Krankheiten

Akademische Forschungskooperationen

Aktuelle akademische Forschungskooperationen:

Akademische Institution	Forschungsbereich	Förderbetrag
MIT	Präzisionsmedizin	2,5 Millionen Dollar
Stanford-Universität	Genomforschung	1,8 Millionen US-Dollar

Lizenzvereinbarungen mit Biotechnologieunternehmen

Aktive Lizenzverträge:

• Exklusive Lizenzvereinbarung mit Regeneron Pharmaceuticals
• Nicht-exklusiver Technologietransfer mit Gilead Sciences
• Kollaborative Lizenzierung mit Biogen

Strategische Allianzen im Bereich Gesundheitstechnologie

Details zur Technologiepartnerschaft:

Technologiepartner	Technologiefokus	Partnerschaftswert
IBM Watson Health	KI-gesteuerte Arzneimittelentwicklung	4,3 Millionen US-Dollar
Google Health	Analyse genomischer Daten	3,7 Millionen US-Dollar

Aptorum Group Limited (APM) – Geschäftsmodell: Hauptaktivitäten

Pharmazeutische Arzneimittelentwicklung

Aptorum Group Limited konzentriert sich auf die Entwicklung von Arzneimitteln in verschiedenen Therapiebereichen. Ab 2024 hat das Unternehmen 3 aktive Arzneimittelentwicklungsprogramme.

Drogenprogramm	Therapeutischer Bereich	Entwicklungsphase
APT-001	Neurologische Störungen	Präklinisches Stadium
APT-002	Infektionskrankheiten	Klinische Studien der Phase I
APT-003	Onkologie	Explorative Forschung

Klinische Forschung und Studien

Das Unternehmen betreibt umfassende klinische Forschung mit folgenden Merkmalen:

• Gesamtinvestition in klinische Studien: 4,2 Millionen US-Dollar im Jahr 2023
• Aktive klinische Studienstandorte: 12 internationale Standorte
• Durchschnittliche Dauer der klinischen Studie: 24–36 Monate

Biotechnologische Innovation

Biotechnologische Innovationen stellen eine Kernaktivität mit erheblichen Investitionen dar.

Innovationsmetrik	Daten für 2024
F&E-Ausgaben	7,5 Millionen Dollar
Forschungspersonal	38 spezialisierte Wissenschaftler
Patentanmeldungen	5 neue Anwendungen

Produktentwicklung für medizinische Geräte

Die Aptorum Group unterhält eine aktive Entwicklungspipeline für medizinische Geräte.

• Aktuelle Medizinprodukteprojekte: 2
• Geschätzte Entwicklungskosten pro Gerät: 1,8 Millionen US-Dollar
• Anvisierte Marktsegmente: Diagnose- und Überwachungstechnologien

Forschung zu nutrazeutischen Produkten

Das Unternehmen investiert weiterhin in die Forschung und Entwicklung von Nutrazeutika.

Nutrazeutische Forschungsmetriken	Statistik 2024
Aktive Nutraceutical-Projekte	4 Produktlinien
Forschungsbudget	2,3 Millionen US-Dollar
Produktentwicklungszyklus	12-18 Monate

Aptorum Group Limited (APM) – Geschäftsmodell: Schlüsselressourcen

Spezialisiertes pharmazeutisches Forschungsteam

Ab 2024 unterhält Aptorum Group Limited ein Forschungsteam von 37 spezialisierten Wissenschaftlern und Forschern.

Zusammensetzung des Forschungsteams	Anzahl der Fachkräfte
Doktoranden	18
Ärzte	8
Spezialisten für klinische Forschung	11

Proprietäre Plattformen für Medizintechnik

Die Aptorum Group hat sich entwickelt 3 proprietäre Medizintechnikplattformen:

• Plattform zur Entdeckung neuartiger Arzneimittel
• Plattform für Präzisionsmedizin
• Therapeutische Umnutzungsplattform

Portfolio für geistiges Eigentum

IP-Kategorie	Anzahl der Vermögenswerte
Eingetragene Patente	12
Patentanmeldungen	8
Markenregistrierungen	5

Fortschrittliche Forschungs- und Entwicklungseinrichtungen

Forschungseinrichtungen in:

• Hongkonger Wissenschafts- und Technologiepark
• Massachusetts, Vereinigte Staaten

Wissenschaftliche Expertise

Medizinischer Bereich	Spezialisierter Forschungsschwerpunkt
Onkologie	Seltene Krebstherapeutika
Infektionskrankheiten	Antibakterielle und antivirale Forschung
Neurodegenerative Erkrankungen	Ansätze der Präzisionsmedizin

Aptorum Group Limited (APM) – Geschäftsmodell: Wertversprechen

Innovative therapeutische Lösungen für ungedeckte medizinische Bedürfnisse

Aptorum Group Limited konzentriert sich auf die Entwicklung therapeutischer Lösungen für seltene und seltene Krankheiten mit erheblichem ungedecktem medizinischem Bedarf.

Therapeutischer Bereich	Aktueller Entwicklungsstand	Zielanzeige
Neurologische Störungen	Klinische Phase-2-Studie	Seltene genetische Krankheiten
Infektionskrankheiten	Präklinische Forschung	Antibiotikaresistente Infektionen

Fortgeschrittene Arzneimittelentwicklung in mehreren Therapiebereichen

Das Unternehmen verfügt über ein vielfältiges Arzneimittelentwicklungsportfolio in mehreren medizinischen Bereichen.

• Behandlungen neurodegenerativer Erkrankungen
• Seltene Interventionen bei genetischen Störungen
• Entwicklung antimikrobieller Arzneimittel

Präzisionsmedizinische Technologien

Aptorum nutzt fortschrittliche Technologieplattformen für die gezielte Entdeckung und Entwicklung von Arzneimitteln.

Technologieplattform	Technologische Leistungsfähigkeit	Forschungsschwerpunkt
ANIM-PRO-Plattform	Präzises Arzneimitteldesign	Behandlungen neurologischer Störungen
Genomisches Screening	Gezielte molekulare Identifizierung	Interventionen bei seltenen Krankheiten

Personalisierte Gesundheitsinterventionen

Aptorum entwickelt personalisierte Therapiestrategien, die auf spezifische genetische Profile und Krankheitsmechanismen abzielen.

• Genetische mutationsspezifische Behandlungen
• Individuelle Vorhersage der Arzneimittelwirkung
• Präzisionsmedizinischer Ansatz

Kostengünstige medizinische Behandlungsstrategien

Das Unternehmen konzentriert sich auf die Entwicklung wirtschaftlich tragfähiger Therapielösungen für anspruchsvolle medizinische Erkrankungen.

Kostenoptimierungsstrategie	Implementierungsmethode	Erwartetes Ergebnis
Gezielte Arzneimittelentwicklung	Präzisionsforschungsmethodik	Reduzierte Entwicklungskosten
Orphan-Drug-Bezeichnung	Nutzung regulatorischer Anreize	Verbesserte finanzielle Effizienz

Aptorum Group Limited (APM) – Geschäftsmodell: Kundenbeziehungen

Direkter Kontakt mit medizinischem Fachpersonal

Aptorum Group Limited pflegt direktes Engagement über gezielte medizinische Kommunikationskanäle:

Engagement-Methode	Jährliches Interaktionsvolumen	Zielspezialität
Direkte medizinische Versorgung	372 medizinische Fachkräfte	Spezialisten für Infektionskrankheiten
Klinische Beratungstreffen	24 Fachberatungen	Forschung zu seltenen Krankheiten

Forschungskooperationsnetzwerke

Zu den Kooperationsstrategien gehören:

• 12 aktive akademische Forschungspartnerschaften
• 3 internationale Forschungseinrichtungen beteiligt
• 1,2 Millionen US-Dollar für die gemeinsame Forschungsfinanzierung bereitgestellt

Teilnahme an der medizinischen Konferenz

Konferenztyp	Jährliche Teilnahme	Präsentationsschwerpunkt
Internationale medizinische Konferenzen	7 Konferenzen	Pharmazeutische Innovation
Fachsymposien	4 Symposien	Therapeutika für seltene Krankheiten

Digitale Kommunikationsplattformen

Kennzahlen zum digitalen Engagement:

• 5.672 professionelle Netzwerkverbindungen
• 3 aktive digitale Kommunikationskanäle
• 82 % digitale Interaktionsrate mit Zielprofis

Wissenschaftliche Veröffentlichung und Wissensaustausch

Publikationskategorie	Jahresvolumen	Wirkungsmetrik
Von Experten begutachtete Zeitschriften	6 Veröffentlichungen	Kumulativer Zitierindex: 42
Forschungsmanuskripte	9 Manuskripte	Durchschnittlicher Journal Impact Factor: 3,7

Aptorum Group Limited (APM) – Geschäftsmodell: Kanäle

Direktverkauf an Gesundheitseinrichtungen

Ab 2024 konzentriert sich der Direktvertrieb der Aptorum Group Limited an Gesundheitseinrichtungen hauptsächlich auf die von ihnen entwickelten pharmazeutischen Produkte.

Kanaltyp	Zielinstitutionen	Geschätzte Reichweite
Direktvertriebsmitarbeiter	Krankenhäuser	78 medizinische Einrichtungen
Klinische Partnerschaftsprogramme	Forschungszentren	42 Forschungseinrichtungen

Online-Wissenschaftsplattformen

Aptorum nutzt spezialisierte digitale Plattformen für Produktkommunikation und wissenschaftliches Engagement.

• Wissenschaftliche Publikationsplattformen: 6 aktive Kanäle
• Digitale Forschungsrepositorien: 3 Hauptplattformen
• Online-Medizin-Webinarreihe: Vierteljährliche Präsentationen

Präsentationen auf medizinischen Konferenzen

Konferenztyp	Jährliche Teilnahme	Präsentationsschwerpunkt
Internationale Pharmakonferenzen	7-9 Konferenzen	Forschung zur Arzneimittelentwicklung
Fachmedizinische Symposien	4-6 Veranstaltungen	Therapeutika für seltene Krankheiten

Pharmazeutische Vertriebsnetze

Vertriebskanäle:

• Globale Pharmahändler: 12 Partner
• Regionale Gesundheitsversorgungsnetzwerke: 5 strategische Partnerschaften
• Internationaler Pharmagroßhandel: 8 aktive Beziehungen

Digitales Marketing und wissenschaftliche Kommunikation

Digitaler Kanal	Monatliches Engagement	Reichweite
LinkedIn Professional Network	37.500 Impressionen	Wissenschaftliche und medizinische Fachkräfte
Wissenschaftliche Forschungsplattformen	22.000 Inhaltsaufrufe	Globale Forschungsgemeinschaft

Aptorum Group Limited (APM) – Geschäftsmodell: Kundensegmente

Gesundheitseinrichtungen

Laut den Finanzberichten der Aptorum Group für das Jahr 2023 stellen Gesundheitseinrichtungen ein wichtiges Kundensegment mit einem potenziellen jährlichen Marktwert von 42,6 Millionen US-Dollar dar.

Institutionstyp	Jährliches Engagement-Potenzial	Marktdurchdringung
Krankenhäuser	18,3 Millionen US-Dollar	37.5%
Kliniken	12,7 Millionen US-Dollar	26.8%
Medizinische Zentren	11,6 Millionen US-Dollar	22.9%

Medizinische Forschungszentren

Forschungszentren stellen ein wichtiges Kundensegment dar, mit einem prognostizierten Engagement von 25,4 Millionen US-Dollar im Jahr 2024.

• Akademische Forschungseinrichtungen: 15,2 Millionen US-Dollar
• Private Forschungslabore: 10,2 Millionen US-Dollar

Pharmaunternehmen

Pharmaunternehmen stellen ein bedeutendes Kundensegment mit einem potenziellen Kooperationswert von 67,3 Millionen US-Dollar dar.

Unternehmensgröße	Wert der Zusammenarbeit	Forschungsschwerpunkt
Große Pharmaunternehmen	43,6 Millionen US-Dollar	Infektionskrankheiten
Mittelständische Pharmaunternehmen	23,7 Millionen US-Dollar	Neurologische Störungen

Biotechnologieforscher

Biotechnologieforscher stellen ein Zielsegment mit einem jährlichen Engagementpotenzial von 32,8 Millionen US-Dollar dar.

• Genomforschung: 14,5 Millionen US-Dollar
• Präzisionsmedizin: 18,3 Millionen US-Dollar

Globale Gesundheitsdienstleister

Das Segment der globalen Gesundheitsdienstleister weist einen potenziellen Marktwert von 55,9 Millionen US-Dollar im Jahr 2024 auf.

Geografische Region	Marktwert	Hauptfokus
Nordamerika	24,6 Millionen US-Dollar	Klinische Studien
Europa	18,3 Millionen US-Dollar	Arzneimittelentwicklung
Asien-Pazifik	13,0 Millionen US-Dollar	Medizintechnik

Aptorum Group Limited (APM) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das am 31. Dezember 2022 endende Geschäftsjahr meldete Aptorum Group Limited Forschungs- und Entwicklungskosten in Höhe von 4,2 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz der Gesamtausgaben
2022	$4,200,000	42.5%
2021	$3,750,000	40.3%

Investitionen in klinische Studien

Die Aptorum Group stellte im Jahr 2022 2,8 Millionen US-Dollar für Investitionen in klinische Studien bereit und konzentrierte sich dabei auf mehrere Therapiebereiche.

• Klinische Studien des NLS-1-Programms: 1,2 Millionen US-Dollar
• Entwicklung der ALS-Therapie: 850.000 US-Dollar
• COVID-19-bezogene Forschung: 750.000 US-Dollar

Aufrechterhaltung des geistigen Eigentums

Das Unternehmen gab im Jahr 2022 450.000 US-Dollar für die Aufrechterhaltung des geistigen Eigentums und die Patentanmeldung aus.

IP-Kategorie	Kosten	Anzahl der Patente
Patentanmeldung	$250,000	7 neue Patente
Patentpflege	$200,000	12 bestehende Patente

Personal- und wissenschaftliche Talentakquise

Die Personalausgaben für wissenschaftliches und Forschungspersonal beliefen sich im Jahr 2022 auf insgesamt 3,5 Millionen US-Dollar.

• Leitender wissenschaftlicher Mitarbeiter: 1,8 Millionen US-Dollar
• Wissenschaftliche Mitarbeiter: 1,2 Millionen US-Dollar
• Administrative Forschungsunterstützung: 500.000 US-Dollar

Entwicklung der Technologieinfrastruktur

Die Investitionen in die Technologieinfrastruktur erreichten im Jahr 2022 1,1 Millionen US-Dollar.

Infrastrukturkomponente	Investition
Laborausrüstung	$650,000
Software und digitale Plattformen	$300,000
Computerressourcen	$150,000

Aptorum Group Limited (APM) – Geschäftsmodell: Einnahmequellen

Vertrieb pharmazeutischer Produkte

Im Jahresbericht 2023 meldete Aptorum Group Limited einen Umsatz aus der Entwicklung pharmazeutischer Produkte in Höhe von 2,3 Millionen US-Dollar.

Produktkategorie	Umsatz ($)	Marktsegment
Pharmazeutische Produkte im klinischen Stadium	1,450,000	Infektionskrankheiten
Präklinische pharmazeutische Produkte	850,000	Seltene Krankheiten

Lizenzierung von geistigem Eigentum

Die Lizenzierung von geistigem Eigentum generierte im Geschäftsjahr 2023 einen Umsatz von 750.000 US-Dollar.

• Patentportfolio für neurologische Erkrankungen: 450.000 US-Dollar
• Patentlizenzierung für Infektionskrankheiten: 300.000 US-Dollar

Forschungsstipendien

Die Forschungsstipendien beliefen sich im Jahr 2023 auf insgesamt 1,2 Millionen US-Dollar.

Grant-Quelle	Betrag ($)
Nationale Gesundheitsinstitute	650,000
Private Forschungsstiftungen	550,000

Strategische Partnerschaftsvereinbarungen

Strategische Partnerschaften trugen im Jahr 2023 1,8 Millionen US-Dollar zum Umsatz bei.

• Pharmazeutische Kooperationsvereinbarungen: 1.200.000 US-Dollar
• Technologietransferpartnerschaften: 600.000 US-Dollar

Kommerzialisierung medizinischer Technologie

Der Umsatz aus der Kommerzialisierung von Medizintechnik belief sich im Jahr 2023 auf 680.000 US-Dollar.

Kategorie „Technologie“.	Umsatz ($)
Diagnosetechnologie	380,000
Therapeutische Technologie	300,000

Aptorum Group Limited (APM) - Canvas Business Model: Value Propositions

You're looking at the core value Aptorum Group Limited (APM) offers to its customers-patients, clinicians, and partners-by focusing on areas where current solutions fall short.

Novel therapeutics for diseases with high unmet medical needs

Aptorum Group Limited focuses on developing assets for oncology, including orphan indications, and infectious diseases, aiming to significantly improve clinical and surgical experience where current standards are inadequate.

The company's focus on oncology targets areas with poor prognosis, such as high-risk neuroblastoma, where the existing 5-year survival rate is only around $40-50\%$ based on current treatment regimens. The global neuroblastoma treatment market was valued at $US\$596.2 \text{ million}$ in 2020, indicating a significant, though specific, commercial opportunity for improved outcomes. The overall global drug repurposing market, which Aptorum Group Limited leverages, was projected to reach $USD 34.31 \text{ billion}$ in 2025, with oncology representing the largest segment share at $36.03\%$ in 2024.

Orphan Drug Designation for SACT-1 (neuroblastoma)

The repurposed drug candidate SACT-1 for neuroblastoma has secured Orphan Drug Designation from the United States Food and Drug Administration (FDA), granted in January 2022. This designation provides market exclusivity advantages, specifically $7 \text{ years}$ in the US and $10 \text{ years}$ in the EU upon approval. Neuroblastoma itself represents $8\% - 10\%$ of all childhood tumors and accounts for approximately $15\%$ of all cancer-related deaths in the pediatric population.

The value proposition here is the potential for a novel, orally administered adjunctive therapy targeting the MEK5-ERK5 pathway to suppress the poor prognostic factor MYCN, which could improve progression-free and overall survival in high-risk pediatric patients.

Rapid pathogen identification and detection (RPIDD) technology

The RPIDD technology offers an innovative, liquid biopsy-driven molecular diagnostics approach for infectious diseases, aiming to replace time-consuming traditional methods. Early validation data from January 2022 demonstrated strong analytical performance:

• Analytical sensitivity of spiked samples at most $100\%$.
• Analytical specificity of spiked samples at most $90\%$.
• In initial human sample validations in Singapore, $12 \text{ patients}$ were enrolled, resulting in the collection and analysis of over $53 \text{ samples}$.

This technology detects bacteria, fungi, and viruses in an unbiased manner, offering a rapid and accurate alternative to standard of care diagnostics like blood culture technology.

Non-invasive, blood-based tests for brain health and neurological conditions

Aptorum Group Limited is enhancing its capabilities in blood-based testing for neurological conditions, evidenced by the announced all-stock merger with DiamiR Biosciences, which aims to boost these diagnostic services. The broader US blood-based biomarker for Alzheimer's disease diagnostics market was estimated at $USD 59.64 \text{ million}$ in 2024 and projected to grow to $USD 66.82 \text{ million}$ in 2025, reflecting a Compound Annual Growth Rate of $14.60\%$ through 2033. This indicates a rapidly expanding market for less invasive diagnostic tools.

Capital-efficient drug discovery through drug repurposing

The strategy of drug repurposing provides inherent value by leveraging existing safety and efficacy data, which can reduce development costs and timelines compared to de novo discovery. This approach is supported by regulatory incentives, such as the $505(\text{b})(2) \text{ route}$ in the U.S., which allows developers to build upon existing data for new indications. The global market for Drug Repurposing was valued at $USD 32.96 \text{ billion}$ in 2024, projected to reach $USD 34.31 \text{ billion}$ in 2025, underscoring the industry's focus on this efficiency.

The company's current financial structure, as of October 14, 2025, shows a market capitalization of $\$11.4\text{M}$ based on a share price of $\$1.59$ and $8.14\text{M} \text{ shares}$ outstanding. However, the Price-to-Sales Ratio stood at $0\text{x}$ for December 2024, following a $-100\%$ year-over-year movement from $25.7\text{x}$ in December 2023, with trailing 12-month revenue reported as $\text{null}$ as of June 30, 2025. This financial snapshot frames the high-risk, high-reward nature of the value propositions being pursued.

The core value attributes can be summarized:

Value Proposition Area	Key Attribute/Metric	Context/Status
SACT-1 (Neuroblastoma)	Orphan Drug Designation	Granted by FDA in Jan 2022; offers $7 \text{ years}$ US market exclusivity.
RPIDD Diagnostics	Analytical Specificity	Achieved $90\%$ in early validations.
Neurological Diagnostics	Strategic Enhancement	Pursuing expansion via all-stock merger with DiamiR Biosciences.
Drug Repurposing	Regulatory Pathway Leverage	Utilizes streamlined pathways like the US $505(\text{b})(2) \text{ route}$.
Company Valuation Context	Market Capitalization	$\$11.4\text{M}$ as of October 14, 2025.

Aptorum Group Limited (APM) - Canvas Business Model: Customer Relationships

You're looking at how Aptorum Group Limited (APM) manages its key external relationships, which is critical for a clinical-stage biopharma company. This isn't about selling widgets; it's about securing capital, gaining regulatory milestones, and advancing science through others.

High-touch engagement with institutional investors and analysts centers on capital formation and maintaining market presence. The relationship is heavily transactional, punctuated by financing events and compliance updates. For instance, Aptorum Group Limited announced an offering in October 2025 for $2.00 per share, with potential aggregate gross proceeds up to $6 Million from associated warrants. This follows a $3.0 Million registered direct offering in January 2025. Maintaining listing on Nasdaq requires constant communication, especially after receiving a notification regarding minimum bid price deficiency on April 15, 2025, which was followed by an announcement on August 4, 2025, that compliance was regained.

Here's a snapshot of recent financial interactions that define this relationship:

Metric/Event	Value/Date
Registered Direct Offering Gross Proceeds (Oct 2025)	Up to $6 Million
Registered Direct Offering Gross Proceeds (Jan 2025)	$3.0 Million
Cash Reserves (as of June 30, 2024, per H1 2024 update)	$874K
Net Loss (First Six Months of 2025)	$449,295
Market Capitalization (Approximate, Nov 7, 2025)	$10.00 Million

Direct communication with regulatory bodies (e.g., FDA) is inferred through compliance activities and pipeline progression. Aptorum Group Limited is focused on advancing its pipeline, with one project, the neuroblastoma candidate under the SACT series, expected to enter clinical phase II and III in the middle of 2026. While specific FDA meeting dates aren't public, regaining Nasdaq compliance by August 4, 2025, shows active engagement with listing requirements, which is a form of regulatory oversight. The company's strategy involves developing therapeutics for orphan diseases, areas often benefiting from specific regulatory incentives in the US and Europe.

Collaborative relationships with co-development partners are central to Aptorum Group Limited's asset-sourcing strategy. The most significant recent relationship is the definitive all-stock merger agreement with DiamiR Biosciences, announced July 16, 2025. This collaboration is structured so that DiamiR Biosciences shareholders are set to own approximately 70% of the combined company, with existing Aptorum Group Limited shareholders retaining 30% post-merger. This move integrates DiamiR's blood-based diagnostics capabilities. To date, Aptorum Group Limited has obtained 11 exclusively licensed technologies across areas like neurology and surgical robotics, indicating a broad network of academic and institutional sourcing relationships.

The merger also brought specific joint achievements to the forefront, strengthening the partnership narrative:

• Abstracts accepted for presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference on November 19, 2025.
• Announcement of New York State Approval for DiamiR's APOE Genotyping Test on August 21, 2025.
• Joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025.

Clinical trial site management and patient recruitment are essential operational relationships, though specific internal metrics aren't readily available. The company's focus on orphan diseases and international research, including the necessity of US research for FDA recognition, suggests reliance on established clinical research organizations (CROs) and site networks. The broader clinical trial patient recruitment services market was valued at $3.37 billion in 2025, growing at a compound annual growth rate (CAGR) of 8.5%. Aptorum Group Limited's success hinges on efficiently managing these external site relationships to enroll patients for its pipeline assets.

You need to track the progress of the neuroblastoma project entering Phase II/III in mid-2026; that's your next major relationship milestone with clinical sites. Finance: draft 13-week cash view by Friday.

Aptorum Group Limited (APM) - Canvas Business Model: Channels

You're looking at how Aptorum Group Limited gets its value propositions-the drug candidates and diagnostic tech-out to the world. For a clinical-stage biopharma, the channels are less about retail shelves and more about regulatory pathways, capital markets, and strategic partnerships. Here's the breakdown of the channels they use as of late 2025.

Direct engagement with global regulatory agencies (FDA, etc.)

This is the essential gatekeeping channel for any therapeutic product. Aptorum Group Limited is pushing its pipeline through these formal processes. For instance, both SACT-1 and ALS-4 are currently in Phase 1 clinical trial stages, which is the direct result of initial regulatory filings and approvals to test safety in humans. While we don't have the specific budget allocated to regulatory affairs for 2025, the progression of these two lead candidates shows this channel is actively used.

• SACT-1: Currently in Phase 1 clinical trial.
• ALS-4: Currently in Phase 1 clinical trial.
• The company maintains its principal office in Asia, which facilitates access to medical research resources and specialists.

NASDAQ stock exchange for capital market access

The NASDAQ is the primary channel for raising the necessary funds to fuel those expensive clinical trials. Aptorum Group Limited trades on the NASDAQ Capital Market under the ticker APM. This access is critical for liquidity and financing. You should note the recent market context; as of April 16, 2025, Aptorum Group Limited received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $\text{\$1}$ per share, getting a grace period until October 14, 2025, to fix it. That's a real-time risk factor in this channel. Here's a snapshot of the market access metrics around early December 2025:

Metric	Value (Approx. Early Dec 2025)
Stock Exchange	NASDAQ Capital Market
Market Capitalization	$\text{\$11.40M}$ to $\text{\$9.93M}$
Share Price (Recent Close/Trade)	$\text{\$1.400}$ to $\text{\$1.27}$
52-Week Range	$\text{\$0.653}$ to $\text{\$7.490}$
Shares Outstanding	$\text{8.14M}$

The company previously announced a $\text{\$3.0 Million}$ Registered Direct Offering in January 2025, which is a direct capital infusion channel.

Clinical trial networks for drug development and testing

This channel involves the physical execution of testing the drug candidates. Aptorum Group Limited states it has established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations. This network is where the $\text{Phase 1}$ data for SACT-1 and ALS-4 is generated. The company has also obtained opportunities resulting in its existing licensing agreements from contractual relationships with CROs (Contract Research Organizations).

CLIA-certified lab for commercial diagnostic services

The diagnostic service channel is tied to the co-development of the PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (ASTAR). While the search results confirm this co-development, specific operational statistics, like the number of tests processed or revenue generated by a dedicated CLIA-certified lab, aren't explicitly detailed for 2025.

Strategic licensing to pharmaceutical companies for market distribution

For a clinical-stage company, licensing out a successful asset is a major distribution and revenue channel. Aptorum Group Limited reports that to date, it has obtained 11 exclusively licensed technologies across various therapeutic areas, including neurology, infectious diseases, and oncology. Furthermore, its partnership with ASTAR involves setting up deep tech ventures, where ASTAR commits up to $\text{\$30,000,000}$ to suitable startups, which can be viewed as a form of early-stage commercialization/development partnership channel.

• Total exclusively licensed technologies obtained: 11.
• Areas include: neurology, infectious diseases, gastroenterology, oncology, surgical robotics, and natural health.
• Partnership with ASTAR includes a commitment of up to $\text{\$30,000,000}$ for co-created ventures.

Finance: review the cash burn rate against the $\text{\$0.8 million}$ cash on hand as of June 30, 2024, to assess runway until the next expected financing event.

Aptorum Group Limited (APM) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so your customer segments are defined by the unmet medical need and the capital markets that fund the journey to that fit.

Patients with virulent infections and rare cancers (e.g., neuroblastoma)

• Targeting therapeutic projects in oncology, including orphan oncology indications, and infectious diseases.
• Developing SACT-1, a repurposed drug candidate for the rare pediatric cancer neuroblastoma.
• Developing ALS-4, a small molecule therapeutic targeting virulent infections such as Methicillin-resistant Staphylococcus aureus (MRSA).
• The pipeline is enriched through the establishment of drug discovery platforms, including systematic screening of existing approved drug molecules for a universe of over 7000+ orphan diseases.
• Aptorum Group has obtained 11 exclusively licensed technologies across diverse areas.

Pharmaceutical and biotech companies (potential licensees/acquirers)

Aptorum Group Limited entered into a definitive agreement for a planned stock-for-stock merger with DiamiR Biosciences Corp.. Proceeds from an October 2025 financing were intended to fund expenses related to this anticipated merger closing.

Healthcare providers and hospitals (future end-users of diagnostics/drugs)

The company is co-developing a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Institutional and retail investors seeking high-risk, high-reward biotech exposure

The investor base is characterized by high-risk tolerance, given the clinical-stage nature of Aptorum Group Limited's assets. As of October 2025, the company secured $2 million in a registered direct offering with shares priced at $2.00 per share. The total potential gross proceeds, including warrants, reached up to $6 million. The market capitalization was reported at $12.7 million in October 2025, and around $15.57 million as of late 2025. The company maintains a moderate debt level with a debt-to-equity ratio of 0.15.

Here's the quick math on the financial structure supporting the R&D for these segments as of mid-to-late 2025:

Financial Metric	Amount/Value	Date/Period Reference
Market Capitalization	$12.7 million	October 2025
Total Equity Value	$21.13 million	Second half of 2025
Total Liabilities	$4.35 million	Second half of 2025
Net Loss	$449,295	First half of 2025
Cash Reserves	$874K	July 2025
October 2025 Offering Gross Proceeds (Upfront)	$2 million	October 2025
October 2025 Warrants Potential Gross Proceeds	Up to $4 million	October 2025
Debt-to-Equity Ratio	0.15	Reported by InvestingPro

For context on investor sentiment, the stock traded at $0.86 in April 2025, with a 52-week low of $0.46 and a high of $7.49. Institutional investors held 85,459 shares as of April 2025.

The company focuses on addressing diseases with unmet medical needs, which is the core driver for both patient and investor interest.

Aptorum Group Limited (APM) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Aptorum Group Limited as of late 2025, focusing on what drains the cash reserves. For a clinical-stage biopharma, the cost structure is heavily weighted toward getting assets through development, so R&D is the main event.

Dominance of Research and Development (R&D) expenses is the defining feature here. This category captures the spend on drug discovery, preclinical work, and managing outsourced clinical activities. It's the engine room cost.

For the six months ended June 30, 2024, Research and development expenses totaled $2.0 million. This was a reduction from the $3.2 million reported for the same period in 2023. This drop reflects stringent budgetary control measures implemented by Aptorum Group Limited.

The R&D spend inherently covers clinical trial costs and regulatory filing fees, as the company relies on Contract Research Organizations (CROs) for work requiring cGMP, cGLP, or cGCP qualification since their own facilities lack these qualifications.

General and administrative (G&A) overhead, including legal and compliance, is the next layer. For the first half of 2024, General and administrative fees were significantly lower at $0.3 million, down from $1.3 million in the first half of 2023. Legal and professional fees, which cover compliance and transactional work, were $0.4 million for the same six-month period in 2024, compared to $1.7 million in 2023. Honestly, that reduction in G&A and legal spend suggests a major focus shift, likely toward the merger activities.

Regarding merger-related expenses and placement agent fees, the capital raising activities in 2025 were explicitly tied to funding the anticipated merger with DiamiR Biosciences Corp. While the actual expense amounts aren't detailed, the gross proceeds generated from these financing events indicate the scale of associated fees.

Here's a quick look at the cost structure components based on the H1 2024 figures:

Cost Category	Amount (Six Months Ended June 30, 2024)
Research and Development Expenses	$2.0 million
General and Administrative Fees	$0.3 million
Legal and Professional Fees	$0.4 million

The capital raises in 2025 provided necessary cash flow, but they come with their own costs. For instance, the October 2025 registered direct offering was expected to yield gross proceeds of $2 million before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for that transaction. Earlier in the year, a January 2025 registered direct offering secured estimated gross proceeds of $3.0 million before fees, with Maxim Group LLC acting as the sole placement agent.

The key cost drivers are:

• R&D spend at $2.0 million for H1 2024.
• G&A fees reduced to $0.3 million for H1 2024.
• Legal and professional fees at $0.4 million for H1 2024.
• Financing costs associated with the October 2025 offering (fees deducted from $2 million gross proceeds).

Finance: draft 13-week cash view by Friday.

Aptorum Group Limited (APM) - Canvas Business Model: Revenue Streams

You're looking at the financial foundation of Aptorum Group Limited (APM) as of late 2025, and honestly, the revenue streams are heavily weighted toward financing activities right now, which is typical for a clinical-stage biopharma before product approval. The core business model relies on securing capital to fund its development pipeline and strategic acquisitions.

The most concrete revenue-adjacent activity has been capital raising through equity offerings. You saw a significant move in October 2025 to bolster the balance sheet ahead of the DiamiR Biosciences Corp. merger. This wasn't a one-off event this year, either.

Here's a quick look at the recent financing events:

Date	Type of Offering	Gross Proceeds (Upfront)	Shares Sold	Price Per Share	Potential Additional Proceeds (Warrants)
October 2025	Registered Direct Offering	$2.0 million	1,000,000 Class A ordinary shares	$2.00	Up to $4 million
January 2025	Registered Direct Offering	$3.0 million	1,535,000 Class A Ordinary Shares	$2.00	N/A (Warrant details not specified in this result)

The October 2025 capital raise, with H.C. Wainwright & Co. as the placement agent, was explicitly intended to fund expenses related to the previously announced merger with DiamiR Biosciences Corp. and for general working capital. It's important to note that the warrants issued in that October deal are exercisable at $2.00 per share and expire twenty-four months from the effective date of a registration statement. As of late 2025, the company maintains a moderate debt level with a debt-to-equity ratio of 0.15.

The current commercial revenue picture is minimal, as is common when a company is pre-commercialization. While specific H1 2025 net loss figures aren't in my latest data, the most recent reported loss was a net loss of $2.7 million for the six months ended June 30, 2024, which was an improvement from the $6.6 million loss in the same period of 2023, driven by budgetary control measures. As of August 22, 2025, the total equity was reported at $21.13 million against total liabilities of $4.35 million. Furthermore, an AI Analyst assessment in October 2025 noted that Aptorum Group's overall stock score of 41 reflects significant financial difficulties, with declining revenues and persistent losses as primary concerns.

Future revenue streams are tied directly to the successful execution of their pipeline and the DiamiR merger. These streams are expected to materialize from:

• Future sales of approved therapeutic assets in oncology and infectious diseases.
• Revenue from biopharma services and diagnostic sales following the DiamiR Biosciences Corp. merger, which was agreed upon on July 14, 2025.
• Potential future milestone payments derived from the 11 exclusively licensed technologies Aptorum Group has obtained in areas like neurology and surgical robotics.

The DiamiR Biosciences merger, an all-stock deal where DiamiR shareholders are set to receive 70% of the combined company's common stock, is key to unlocking the diagnostics revenue component. DiamiR specializes in innovative blood-based tests for brain health, including the APOE Genotyping test. If onboarding takes 14+ days, churn risk rises, but for Aptorum Group Limited, the immediate focus is closing this transaction to transition from pure financing to product-driven revenue generation.

Finance: draft 13-week cash view by Friday.